Biogen Idec: Pipeline, Products, Performance, Potential

Table of Contents

• Breaking News
• Latest Results

EXECUTIVE SUMMARY

• Introduction
• Current Financial Position
  • Company Performance
  • Business Segment Performance
  • Geographic Segment Performance
• Company Strategy
  • R&D Strategy
  • Mergers, Acquisitions and Divestitures
  • Key Agreements
  • Production
  • Employees
• Product Performance Forecasts
• Pipeline Analysis
• Other Factors Affecting the Bottom Line
• Conclusions/Outlook

THERAPEUTIC AREA FOCUS

R&D PIPELINE

ONCOLOGY

• Marketed Products
  • Rituxan
• R&D Projects
  • BIIB021
  • Galiximab
  • Lumiliximab
  • Volociximab
• Growth Forecast

CENTRAL NERVOUS SYSTEM

• Marketed Products
  • Avonex
  • Tysabri
• R&D Projects
  • BIIB014
  • BG-12
  • CDP323
  • Daclizumab
  • Ocrelizumab
• Growth Forecast

IMMUNOLOGY

• Marketed Products
  • Rituxan
  • Fumaderm
• R&D Projects
  • LTBR-Fc
  • Ocrelizumab
• Growth Forecast

OTHERS

• R&D Projects
  • Adentri
  • Aviptadil
  • Lixivaptan

APPENDIX 1 - FINANCIAL PERFORMANCE

• Full Year Results 2007

APPENDIX 2 - KEY CO RPORATE EVENTS

APPENDIX 3 - KEY AGREEMENTS

• Alnylam Pharmaceuticals Inc
• Astellas Pharma
• Bayer
• Brain Science Institute, Johns Hopkins University
• Cardiokine Biopharma LLC
• Cell Therapeutics Inc
• Celltech Group Plc
• Chemical Diversity Labs Inc
• Fumedica GmbH
• Genaissance Pharmaceuticals Inc
• GlycoFi Inc
• Lexicon Genetics Inc
• mondoBIOTECH AG
• MorphoSys AG
• NeoGenesis Pharmaceuticals Inc
• Neurimmune SubOne AG
• PDL BioPharma Inc
• Pharmaceutical Product Development Inc (PPD)
• Rentschler Biotechnologie GmbH
• Roche
• Schering-Plough
• Sunesis Pharmaceuticals Inc
• Tanox Inc
• The Medicines Company
• UCB
• Vernalis Plc
• Xenogen Corp

APPENDIX 4 - INFRASTRUCTURE

• Research and Development Facilities
• Manufacturing Facilities

APPENDIX 5 - KEY PHARMACEUTICAL SUBSIDI ARIES/JOINT VENTURES

• Subsidiaries
• Joint Ventures

APPENDIX 6 - PRODUCT INDEX

Index of Tables

• Principal Operating Results
• Sales By Business Segment
• Sales By Geographic Area
• Product Sales By Geographic Area
• Long-Term Assets By Geographical Area
• Recent Product Approvals
• Major Therapeutic Areas And Sales
• Major Oncology Products, 2007
• Major Central Nervous System Products, 2007
• Major Immunology Products, 2007

Index of Charts

• Sales By Business Area
• Sales By Geographic Area
• Product Sales By Geographic Area
• Long-Term Assets By Geographical Area
• Sales of Top 4 Products (2003A-2012E)
• Sales of Top Products, 2007
• Rituxan Sales (2002A-2012E)
• Avonex Sales (2003A-2012E)
• Tysabri Sales (2004A-2012E)
• Ocrelizumab Sales (2011E-2015E)
• Rituxan Sales (2002A-2012E)
• Fumaderm Sales (2006A-2012E)
• Ocrelizumab Sales (2011E-2015E)
• Sales, Costs and Operating Income
• Profitability and Research Ratios
• R&D Expenditure and Capital Expenditure
• Current Assets, Liabilities and Ratio
• Assets, Cash and Liquidity
• Employees and Productivity